{"id":481561,"title":"Notice: Multiple additions to the Prescription Drug List (PDL) [2022-10-14] - Canada.ca","sourceCode":"hc","sourceName":"Health Canada","language":"en","captureDate":"2026-01-06","captureTimestamp":"2026-01-06T16:58:31.225000+00:00","jobId":6,"originalUrl":"https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/prescription-drug-list/notices-changes/multiple-additions-2022-10-14.html?wbdisable=true","snippet":"Notice: Multiple additions to the Prescription Drug List (PDL) October 14, 2022 Our file number: 22-110895-558 The purpose of this Notice of Amendment is to notify about the addition of abrocitinib, asciminb, belzutifan, difelikefalin, maribavir and tezepelumab to the…","rawSnapshotUrl":"/api/snapshots/raw/481561","browseUrl":"https://replay.healtharchive.ca/job-6/20260106165831/https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/prescription-drug-list/notices-changes/multiple-additions-2022-10-14.html?wbdisable=true#ha_snapshot=481561","mimeType":"text/html","statusCode":200,"captureBackend":"browsertrix","captureFidelity":"high"}